Showing results (2071-2080 of 2,317) with videos related to

Sort By:
Pageof 232
Nature Communications|September 6, 2022
Adipocyte-derived lactate is a signalling metabolite that potentiates adipose macrophage inflammation via targeting PHD2Tianshi Feng, Xuemei Zhao, Ping Gu, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|August 1, 2006
[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer]Jun-ling Li, Xiang-ru Zhang, Ji-wei Liu, et al.
Cancer Letters|June 19, 2017
A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancerYee Syuen Low, Christopher Blöcker, John R McPherson, et al.
Frontiers in Oncology|December 9, 2022
Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 studyJingzhu Zhao, Yihebali Chi, Chuanxiang Hu, et al.
Cancers|April 26, 2020
Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing ImmunotherapyWai Nam Liu, Shin Yie Fong, Wilson Wei Sheng Tan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 30, 2020
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407Luis Paz-Ares, David Vicente, Ali Tafreshi, et al.
The Lancet. Respiratory Medicine|March 29, 2021
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label studyYuankai Shi, Xingsheng Hu, Shucai Zhang, et al.
JTO Clinical and Research Reports|September 16, 2024
Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA StudyCaicun Zhou, You Lu, Sang-We Kim, et al.
The Lancet. Oncology|September 30, 2017
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trialYi-Long Wu, Ying Cheng, Xiangdong Zhou, et al.
Journal of Pineal Research|November 18, 2020
Deletion of ferritin H in neurons counteracts the protective effect of melatonin against traumatic brain injury-induced ferroptosisTongyu Rui, Haochen Wang, Qianqian Li, et al.
Pageof 232